RT Journal Article
SR Electronic
T1 Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.27.20162693
DO 10.1101/2020.07.27.20162693
A1 Uyoga, Sophie
A1 M.O. Adetifa, Ifedayo
A1 Karanja, Henry K.
A1 Nyagwange, James
A1 Tuju, James
A1 Wanjiku, Perpetual
A1 Aman, Rashid
A1 Mwangangi, Mercy
A1 Amoth, Patrick
A1 Kasera, Kadondi
A1 Ng’ang’a, Wangari
A1 Rombo, Charles
A1 Yegon, Christine
A1 Kithi, Khamisi
A1 Odhiambo, Elizabeth
A1 Rotich, Thomas
A1 Orgut, Irene
A1 Kihara, Sammy
A1 Otiende, Mark
A1 Bottomley, Christian
A1 N. Mupe, Zonia
A1 W. Kagucia, Eunice
A1 E Gallagher, Katherine
A1 Etyang, Anthony
A1 Voller, Shirine
A1 N. Gitonga, John
A1 Mugo, Daisy
A1 N. Agoti, Charles
A1 Otieno, Edward
A1 Ndwiga, Leonard
A1 Lambe, Teresa
A1 Wright, Daniel
A1 Barasa, Edwine
A1 Tsofa, Benjamin
A1 Bejon, Philip
A1 I. Ochola-Oyier, Lynette
A1 Agweyu, Ambrose
A1 Scott, J. Anthony G.
A1 Warimwe, George M.
YR 2020
UL http://medrxiv.org/content/early/2020/07/29/2020.07.27.20162693.abstract
AB Background There are no data on SARS-CoV-2 seroprevalence in Africa though the COVID-19 epidemic curve and reported mortality differ from patterns seen elsewhere. We estimated the anti-SARS-CoV-2 antibody prevalence among blood donors in Kenya.Methods We measured anti-SARS-CoV-2 spike IgG prevalence by ELISA on residual blood donor samples obtained between April 30 and June 16, 2020. Assay sensitivity and specificity were 83% (95% CI 59-96%) and 99.0% (95% CI 98.1-99.5%), respectively. National seroprevalence was estimated using Bayesian multilevel regression and post-stratification to account for non-random sampling with respect to age, sex and region, adjusted for assay performance.Results Complete data were available for 3098 of 3174 donors, aged 15-64 years. By comparison with the Kenyan population, the sample over- represented males (82% versus 49%), adults aged 25-34 years (40% versus 27%) and residents of coastal Counties (49% versus 9%). Crude overall seroprevalence was 5.6% (174/3098). Population-weighted, test- adjusted national seroprevalence was 5.2% (95% CI 3.7– 7.1%). Seroprevalence was highest in the 3 largest urban Counties - Mombasa (9.3% [95% CI 6.4-13.2%)], Nairobi (8.5% [95% CI 4.9-13.5%]) and Kisumu (6.5% [95% CI 3.3-11.2%]).Conclusions We estimate that 1 in 20 adults in Kenya had SARS-CoV-2 antibodies during the study period. By the median date of our survey, only 2093 COVID-19 cases and 71 deaths had been reported through the national screening system. This contrasts, by several orders of magnitude, with the numbers of cases and deaths reported in parts of Europe and America when seroprevalence was similar.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was funded by the Wellcome Trust (220991/Z/20/Z; 203077/Z/16/Z). Sophie Uyoga is funded by DELTAS Africa Initiative [DEL-15-003], Isabella Ochola-Oyier is funded by a Wellcome Trust Intermediate Fellowship (107568/Z/15/Z), Ambrose Agweyu is funded by a DFID/MRC/NIHR/Wellcome Trust Joint Global Health Trials Award (MR/R006083/1), J. Anthony G Scott is funded by a Wellcome Trust Senior Research Fellowship (214320) and the NIHR Health Protection Research Unit in Immunisation, Ifedayo Adetifa is funded by an MRC/DFID African Research Leader Fellowship (MR/S005293/1) and by the NIHR-MPRU at UCL (grant 2268427 LSHTM). GMW is supported by a fellowship from the Oak Foundation. Charles N. Agoti is funded by the DELTAS Africa Initiative [DEL-15-003], and the Department for International Development and Wellcome (220985/Z/20/Z). The authors did not received payment or services from a third party.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Scientific and Ethics Review Unit (SERU) of the Kenya Medical Research Institute.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data and analysis scripts for this manuscript shall be made available at the KWTRP Harvard Dataverse: (https://dataverse.harvard.edu/dataverse/kwtrp). Some of the clinical dataset contains potentially identifying information on participants and is stored under restricted access. Requests for access to the restricted dataset should be made to the Data Governance Committee (dgc@kemri-wellcome.org) of the KEMRI-Wellcome Trust Research Programme.